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1. Introduction
Clostridium difficile (CD) diarrhea is a serious, infectious compli-
cation related to antibiotic exposure, which has been shown to
prolong hospital stays and increase morbidity and mortality. C.
difficile infection (CDI) in the intensive care unit (ICU) setting is
particularly troublesome leading to an increase in attributable
hospital mortality, prolonged ICU stay, and greater number of
days in the hospital [1]. Exact incidence rates for CDI in the ICU
setting have varied from 4.4 to 32 cases per 10,000 patient days
[2–4]. Risk factors for CDI in the ICU do not differ significantly
from commonly accepted risk factors identified in the general
hospital setting: advanced age, prolonged hospitalization, severe
underlying disease, concomitant infections, proton pump
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With improved survival in burn patients, Clostridium difficile infection (CDI) remains a
significant potential complication. The incidence of, risk factors for, and outcomes of
CDI in severely burned patients are poorly studied and remain unclear. This study involves
retrospective case control and cohort studies using electronic medical records from Febru-
ary 1, 2002 to January 31, 2009 at the US Department of Defense’s only burn unit. Demo-
graphic, risk factor, and outcome data were collected for all C. difficile toxin positive patients
in the burn, medical, and surgical intensive care units and the hospital’s step down unit
along with an additional analysis of a 2:1 matched control of C. difficile toxin negative to
positive burn patients. In the burn intensive care unit (BICU) population there was an
incidence of 7.9 cases per 10,000 patient days; less than the non-burn unit rate of 15.2 cases
( p-value < 0.01). The BICU patients were young males with a median 42% total body surface
area burns. There were higher frequencies of operations and prior aminoglycoside use, with
longer unit stays and times until death or discharge. There was no difference in treatments,
morbidity, or mortality. The comparison of patients with positive and negative C. difficile
toxin among those in the BICU revealed few significant differences in risk factors or
outcomes. Differences in risk factors between burn and non-burn patients were likely
markers of the populations rather than independent risk factors for CDI in the burn
population with overall lower rates likely reflective of younger, healthier patients in the
BICU and more aggressive infection control practices.
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inhibitor use, recent gastrointestinal surgeries, enteral feeding
tube placement, and antibiotic exposure [5,6]. Although cepha-
losporins, clindamycin, and broad-spectrum antibiotics have
been implicated in the development of CDI, a wide range of
antimicrobials have shown association with the disease
whether as actual predisposing agents or simple markers for
other established risk factors [7,8].
Burn patients are at high risk for infectious complications
during their hospitalizations due to alterations in their skin
and mucosal barriers, general altered physiology in response
to the stress of injury, and increased incidence of established
risk factors such as prolonged hospital stays, significant
antibiotic exposure, frequent need for surgical intervention,
and use of proton pump inhibitors. The only study to date on
CDI conducted in a burn unit specifically was carried out in
1987 and had a limited number of patients yielding a
prevalence of 7.65% [9]. With improvement in burn care since
this time, extended survival in severely burned patients has
allowed more time for infectious complications to occur [10]. It
was with this in mind that we set out to further characterize
the incidence, risk factors, and outcomes of CDI in severely
burned patients admitted to the ICU.
2. Methods
Retrospective cohort and case control studies were undertak-
en utilizing an electronic medical records review of the Brooke
Army Medical Center medical and surgical ICUs and step down
unit in addition to the US Army Institute of Surgical Research
(USAISR) Burn Center intensive care unit (BICU) from February
01, 2002 to January 31, 2009. BAMC is a 240-bed, verified Level 1
trauma center, serving both DoD beneficiaries and civilian
emergency patients within the southern Texas region trauma
system. BAMC operates 48 ICU bed designated for surgical,
medical and cardiac intensive care patients. The 40-bed
USAISR Burn Center within the BAMC facility includes a 16-
bed BICU, and adjacent dedicated operating room suite. The
surgical intensive care units (SICU) (2N and 2S) and medical
intensive care units (MICU) (3S) are both semi-closed units
caring for critically ill patients deemed in need of intensive
care while the step down unit (3N) is typically composed of
medical patients followed by general medicine staff requiring
closer monitoring outside the intensive care unit setting.
Standard care the burn center includes early excision and
grafting and implementation of aggressive infection control to
include strict contact precautions in individual rooms
throughout the BICU admission. In all wards evaluated in
this study, patients are admitted to single patient rooms with
the implementation of contact precautions when patients
develop diarrhea along with placards indicating that hand
hygiene should involve soap and water. Periodic hand hygiene
compliance surveys have indicated relatively consistent
adherence across the various ICUs. Due to the fact that some
SICU and MICU patients are housed in alternate units due to
overflow and that our study is focused on investigating an
infectious disease with close association to contact exposures
it was decided to differentiate the non-burn ICUs by
geographic location (2N, 2S, 3N, 3S) rather than patient type;
care of burn patients is restricted to the BICU.
For the cohort study, all patients admitted to the BICU, non-
burn ICUs, or step down units were screened with the
electronic clinical microbiologic culture database for CD toxin
screening in the stool. All patients identified with positive CD
toxin assays were included in the study with the exception of
patients with non-thermal burns who were excluded from the
BICU cohort. CD toxin throughout the healthcare facility was
obtained at the discretion of the clinician based upon the
presence of fevers and/or elevated white blood cell count
without a clear etiology along with the presence of diarrhea.
Patients were then further evaluated by demographics (age
and gender) and potential risk factors for CDI (time until
positive, presence and duration of feeding tubes, mechanical
ventilation, number of total and GI surgeries, and proton
pump inhibitor (PPI) and prior antibiotic exposure). The
patient’s clinical condition on day of positive CD toxin assay
was evaluated using the systemic inflammatory response
syndrome (SIRS) and burn sepsis criteria as detailed American
College of Chest Physicians/Society of Critical Care Medicine
and American Burn Association Consensus Conferences,
respectively [13,14]. Treatments and outcomes were recorded
to include antibiotic choice, incidence of toxic colitis, length of
unit stay and time to death or discharge, and any cases of in-
hospital mortality. Prior antibiotic use was defined as the
receipt of any antibiotics inpatient or outpatient within 60
days prior to positive toxin assay. To further simplify
management of antibiotic data, each agent was classified
into one of six groups consisting of cephalosporins, fluor-
oquinolones, parenteral vancomycin, aminoglycosides, peni-
cillin derivatives (non-cephalosporin beta-lactams), and a
final group to include all others. PPI use was identified if given
within 60 days prior to positive toxin assay.
For the case control study, a 1:2 matched positive to
negative CD toxin results for BICU patients were matched by
time of admission (19 months), age (15 years), gender, and
TBSA (15%). Charts were evaluated via the methods outlined
in the cohort study with additional burn characteristics data
(% total body surface area (TBSA), full thickness burns, and the
presence of inhalation injury).
Statistical analyses were performed using the statistical
software SPSS. Descriptive frequencies were expressed
using medians with ranges provided. When comparing
CDI positive burn patients with CDI negative burn patients,
these patients were matched in a 2:1 fashion by gender, age
and %TBSA. Continuous data was evaluated using a
repeated measures ANOVA while nominal and ordinal data
was evaluated by the Friedman test. CDI positive burn
patients were compared with patients in multiple other
(non-burn) intensive care units. These patients were not
matched. For non-normally distributed data that was
continuous, the differences between populations were
evaluated with the Mann–Whitney U test. For categorical
data comparisons, the chi-square test was used. No variable
was normally distributed. Incidence rates were calculated
by dividing total cases of CDI in each unit by total number of
patient bed days for each unit. Due to limitations in hospital
bed day data, only the study periods after January 01, 2004
were included in the bed day analysis. In addition, rates
were determined by number of patients with tests for CDI by
the number with positive tests.
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3. Results
During the study period, 14 patients developed CDI while
hospitalized in the BICU among the 180 tested. Thirteen of
these patients developed CDI in the time period we have total
admissions data for, as there was insufficient records from
2002 to 2003, revealing an infection rate of 7.9 cases per 10,000
patient days (Table 1). Among the non-burn ICUs, there were
11, 16, 18, and 28 cases among the 77, 97, 93, and 169 tested in
3N, 2S, 2N, and 3S, respectively. The overall rates for these
Table 1 – Incidence rates of Clostridium difficile diarrhea for each unit by number tested and patient bed days.a.
Cases of CDI Number of
patients tested
Number of
patient days
Cases of CDI
per patient tested
Cases of CDI per
10,000 patient daysc
BICU
2002 1 14 0.07
2003 0 23 0.00
2004 3 25 2005 0.12 15.0
2005 6 31 3841 0.19 15.6
2006 4 36 3754 0.11 10.7
2007 0 30 3401 0.00 0.0
2008 0 21 3358 0.00 0.0
2009b 0 0 0.00
Total 14 180 16,359 0.08 7.9
3N
2002 6 13 0.46
2003 5 15 0.33
2004 2 20 2694 0.10 7.4
2005 4 15 2866 0.27 14.0
2006 2 13 2697 0.15 7.4
2007 0 13 2657 0.00 0.0
2008 3 16 2780 0.19 10.8
2009b 0 0 0.00
Total 22 105 13,694 0.21 8.0
3S
2002 3 26 0.12
2003 5 36 0.14
2004 9 37 2345 0.24 38.4
2005 5 44 2645 0.11 18.9
2006 8 29 2455 0.28 32.3
2007 4 33 2401 0.12 16.7
2008 2 26 2316 0.08 8.6
2009b 0 0 0.00
Total 36 231 12,162 0.16 23.0
2N
2002 4 9 0.44
2003 3 17 0.18
2004 2 21 2217 0.10 9.0
2005 9 14 2351 0.64 38.3
2006 2 16 2331 0.12 8.6
2007 3 24 2265 0.12 13.2
2008 2 18 1897 0.11 10.5
2009b 0 0 0.00
Total 25 119 11,061 0.21 16.3
2S
2002 2 24 0.08
2003 1 23 0.04
2004 4 20 2167 0.20 18.5
2005 2 20 2543 0.10 7.9
2006 6 16 2379 0.38 25.2
2007 2 24 2115 0.08 9.5
2008 2 17 1967 0.12 10.2
2009b 0 0 0.00
Total 19 144 11,171 0.13 14.3
a Incidence data is only for patients admitted after January 1, 2004.
b Data through 1 January 2009, so no rates provided.
c Patient days are for all admissions to the unit.
b u r n s 3 7 ( 2 0 1 1 ) 4 2 – 4 844
non-burn ICUs were generally higher at 8.0, 14.3, 16.3, and 23.0
cases per 10,000 patient days in 3N, 2S, 2N, and 3S,
respectively. Overall, the BICU infection rate was significantly
lower than the combined non-burn ICU and step down unit
average of 15.2 cases per 10,000 patient days.
3.1. Characteristics, interventions, and outcomes in
cohort study
The median age of the CDI positive BICU patients was 25.5
(range 19–72) and 92.2% were male while in the non-burn ICUs
and step down unit the median ages of CDI positive patients
were significantly older (median 70, range 19–94) with a
smaller proportion of males (58.4%) (Table 2).
CDI positive BICU patients tended to have longer unit stays
(median 26.0 days, range 4–98) relative to CDI positive patients
in the non-burn ICUs and step down unit (median 13.0 days,
range 1–154) (p-value <0.01). CDI positive BICU patients also
underwent significantly more surgical procedures (median 2.0
[range 0–18] vs. 0.0 [range 0–18], p-value <0.01) though there
was a high degree of variability with this depending on
whether the patient was cared for by a SICU or MICU team (see
Table 2). Antibiotic treatment prior to the diagnosis of CDI was
similar across most units though BICU patients received
greatly increased amounts of aminoglycosides (78.6% vs.
20.8%, p-value <0.01) and slightly less cephalosporins (14.3%
vs. 49.5%, p-value 0.013). Clinically BICU patients positive for
CDI had greater body temperatures at time of diagnosis with
Table 2 – Characteristics of Clostridium difficile confirmed diarrhea patients in all intensive care units.
BICU
(N = 14)
2N
(N = 25)
2S
(N = 19)
3N
(N = 21)
3S
(N = 36)
All ICU
except
BICU
(N = 101)
p-Values
for BICU
vs. all
other ICUs
Age (range) 25.5 (19–72) 73.0 (20–91) 68.0 (25–87) 58.0 (19–94) 68.5 (37–88) 70.0 (19–94) <0.01
Male gender (%) 13 (92.9%) 19 (76%) 8 (42.1%) 10 (47.6%) 22 (61.1%) 59 (58.4%) 0.016
Days in unit (range) 26.0 (4–98) 15.0 (2–58) 26.0 (2–154) 23.0 (2–42) 8.5 (1–28) 13.0 (1–154) 0.018
Days on ventilator (range) 0 (0–41) 3.0 (0–50) 3.0 (0–39) 0 (0–29) 0 (0–46) 0 (0–50) 0.549
# of surgeries (range) 2.0 (0–18) 1.0 (0–18) 1.5 (0–10) 1.0 (0–9) 0 (0–2) 0 (0–18) <0.01
# of gastrointestinal
surgeries (range)
0 (0–1) 0 (0–8) 0 (0–2) 0 (0–3) 0 (0) 0 (0–8) 0.508
Antibiotics in past 60 days
Cephalosporins 2 (14.3%) 14 (56.0%) 9 (47.4%) 8 (38.1%) 19 (52.8%) 50 (49.5%)
Fluoroquinolones 7 (50%) 16 (64.0%) 13 (68.4%) 10 (47.6%) 27 (75.0%) 66 (53.0%) 0.013
Vancomycin 11 (78.6%) 18 (72.0%) 11 (57.9%) 11 (52.4%) 22 (61.1%) 62 (61.4%) –
Aminoglycosides 11 (78.6%) 9 (36.0%) 3 (15.8%) 5 (23.8%) 4 (11.1%) 21 (20.8%) –
Penicillin derivatives 9 (64.3%) 19 (76.0%) 15 (78.9%) 13 (61.9%) 24 (66.7%) 71 (70.3%) <0.01
Other 3 (21.4%) 9 (36.0%) 8 (42.1%) 8 (38.1%) 14 (38.9%) 39 (38.6%) –
Proton pump inhibitor
use (%)
14 (100%) 22 (88%) 18 (94.7%) 15 (71.4%) 29 (80.6%) 82 (82%) 0.121
Days from admit to
diagnosis (range)
10 (1–92) 11 (0–59) 17 (0–41) 5 (0–32) 3.5 (0–27) 7 (0–59) 0.091
SIRS-temperaturea (%) 12 (85.7%) 9 (36.0%) 10 (52.6%) 10 (47.6%) 12 (33.3%) 41 (41%) <0.01
SIRS-respiratory rate 10 (71.4%) 21 (84%) 17 (17%) 18 (85.7%) 32 (88.9%) 88 (87.1%) 0.219
SIRS-heart rate 12 (85.7%) 21 (84%) 14 (73.3%) 18 (85.7%) 26 (72.2%) 79 (78.2%) 0.731
SIRS-white blood
cell count
10 (71.4%) 15 (60%) 12 (63.2%) 18 (85.7%) 21 (58.3%) 62 (61.3%) 0.467
Sepsis (%) 12 (85.7%) 22 (88%) 16 (84.2%) 20 (38.1%) 32 (88.9%) 90 (89.1%) 0.658
Treatment (%)
Nothing 1 (7.1%) 1 (4.0%) 0 0 3 (8.3%) 4 (4.0%) 0.695
Metronidazole (IV) 12 (85.7%) 18 (72.0%) 15 (78.9%) 17 (81.0%) 28 (77.8%) 78 (77.2%)
Vancomycin (PO) 0 2 (8.0%) 0 0 1 (2.8%) 3 (3.0%)
Both 1 (7.1%) 4 (16.0%) 4 (21.2%) 4 (19.0%) 4 (11.1%) 16 (15.8%)
Morbidity (%)
Colectomy 0 1 (4.0%) 2 (10.5%) 1 (4.8%) 1 (2.8%) 5 (5.0%) 0.597
Toxic colitis 0 0 1 (5.3%) 0 1 (2.8%) 2 (2.0%)
Mortality (%) 4 (28.6%) 7 (28%) 6 (31.6%) 0 12 (33.3%) 25 (24.8%) 0.749
Attributable mortality
(% of deaths)
0 1 (14%) 3 (50%) 0 5 (42%) 9 (36%) 0.273
Days to death or
discharge (range)
43 (6–152) 15 (2–79) 21 (2–212) 10 (1–60) 7 (0–53) 11 (0–212) <0.01
a SIRS-temperature: <36 8C or >38 8C; SIRS-respiratory rate: >20 breaths/min or PCO2 <32 mm Hg; SIRS-heart rate: >90 beats/min; SIRS-white
blood count: <4000 cells/mm3 or >12,000 cells/mm3 or >10% band forms. All as defined by 1992 American College of Chest Physicians/Society
of Critical Care Medicine Consensus Conference.
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85.7% meetings SIRS criteria for temperature versus 41% of CDI
positive patients in the non-burn ICUs and step down unit (p-
value <0.01). This was the only one of the four SIRS criteria
that was significantly different, however, and overall there
was no statistically significant difference in the incidence of
sepsis in BICU patients versus patients in the other units.
CDI positive patients in the BICU had significantly longer
times till death or discharge (median 43 days, range 6–152)
relative to CDI positive patients in the non-burn ICUs and the
step down unit (median 11 days, range 0–212) (p-value <0.01).
There was no significant difference in the treatment,
morbidity, or mortality of CDI positive patients in all
populations studied (see Table 3). Although no further
treatment was rendered in burns while 5 of 101 in the other
groups underwent colectomy or developed toxic colitis. The
majority of patients received parenteral metronidazole in all
units (range 72.0–85.7%) with the remainder typically receiving
both parenteral metronidazole and oral vancomycin (range
7.1–21.2%). There was no difference in the incidence of toxic
colitis or need for colectomy and mortality was 28.6% in the
BICU compared to 24.8% in all other intensive care and step
down units (p-value 0.749). There was no attributable
mortality in the BICU, however, and attributable mortality
was variable in the other ICUs (range 14.3–50.0% of deaths)
though none of this was statistically significant.
3.2. Characteristics and outcomes in case control study
The median age of the CDI negative BICU patients was 29
(range 20–72) and 92.9% were male as matched (Table 3). With
regards to their burns, the median TBSA was 43% (range 1–
77.5%) as matched and there was no significant difference in
the incidence of full thickness burns or inhalation injury.
Relative to the CDI positive burn patients, the CDI negative
burn patients underwent more surgeries (median 4.0 [range 0–
14] vs. 2.0 [range 0–18], p-value 0.019) and on average stayed
longer in the BICU (median 38.0 days [range 9–228] vs. 26.0 days
[range 4–98], p-value<0.01). With regards to antibiotic therapy
Table 3 – Characteristics of burned patients with and without Clostridium difficile confirmed diarrhea.
C. difficile positive (N = 14) C. difficile negative (N = 28) p-Value
Age (range) 25 (19–72) 29 (20–72) Matching criteria
Male gender (%) 13 (92.2%) 26 (92.9%) Matching criteria
TBSA (%) 42 (25) 43 (23) Matching criteria
Full thickness burn (%) 12 (85.7%) 25 (89.3%) 0.607
Inhalation injury (%) 7 (50.0%) 12 (42.9%) 0.670
Days in unit (range) 26.0 (4–98) 38.0 (4–228) <0.01
Days on ventilator (range) 0.0 (0–41) 0.0 (0–92) <0.01
# of surgeries (range) 2 (0–18) 4 (0–14) 0.019
# of gastrointestinal surgeries (range) 0 (0–1) 0 (0–2) 0.735
Antibiotics in past 60 days (%)
Cephalosporins 2 (14.3%) 4 (14.3%)
Fluoroquinolones 7 (50%) 11 (39.3%) 0.05
Parenteral vancomycin 11 (78.6%) 26 (92.9%)
Aminoglycosides 11 (78.6%) 28 (100%)
Penicillin derivatives 9 (64.3%) 23 (82.1%)
Other 3 (21.4%) 10 (35.7%)
Proton pump inhibitor use (%) 14 (100%) 28 (100%) 1.0
Days from admit to diagnosis (range) 10 (1–92) N/A
SIRS-temperaturea (%) 12 (85.7%) 24 (85.7%) 0.549
SIRS-respiratory rate 10 (71.4%) 24 (85.7%) 0.449
SIRS-heart rate 12 (85.7%) 28 (100%) 0.135
SIRS-white blood cell count 10 (71.4%) 18 (64.3%) 0.895
Sepsis (%) 12 (85.7%) 27 (96.4%) 0.368
Treatment (%)
Nothing 1 (7.1%)
Metronidazole (IV) 12 (85.7%)
Vancomycin (PO) 0
Both 1 (7.1%)
Morbidity (%)
Colectomy 0
Toxic colitis 0
Mortality (%) 4 (28.5%) 12 (42.9%) 0.641
Attributable mortality (% of deaths) 0
Days to death or discharge (range) 43.0 (6–152) 26.5 (1–112) <0.01
a Systemic inflammatory response system (SIRS)-temperature: <36 8C or >38 8C; SIRS-respiratory rate: >20 breaths/min or PCO2 < 32 mm Hg;
SIRS-heart rate: >90 beats/min; SIRS-white blood count: <4000 cells/mm3 or >12,000 cells/mm3 or >10% band forms. All as defined by 1992
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
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prior to testing for CDI, the CDI negative patients received
aminoglycoside antibiotics in greater frequency than the CDI
positive patients (100% vs. 78.6%, p-value 0.05) with no other
significant differences in therapy. The time to death or
discharge from the hospital after time of testing was
significantly shorter for the CDI negative burn patients at
26.5 days (range 1–112, p-value<0.01). Twelve (42.9%) of the 28
CDI negative BICU patients died (vs. 28.6% of the 14 CDI
positive BICU patients) during their admission though this
mortality difference was not significant (p-value 0.641).
4. Discussion
C. difficile infection continues to remain an important problem
and perennial complication of hospitalization but appears less
so in BICU patients versus patients admitted to other ICUs.
With its association with significant morbidity and mortality
and its potentially preventable nature, attention must be paid
to its various risk factors and general evolution over time.
Advances in burn care, including early excision and grafting,
have yielded improved survival over the past 30 years thus
compelling greater attention to hospital associated complica-
tions [15,16].
Although methods of reporting have varied, CDI rates in the
ICU in general have fluxed in recent studies with the Centers
for Disease Control and Prevention reporting 5.0 cases per
10,000 patient days from 1987 to 2001 in the National
Healthcare Safety Network (known previously as the NNISS)
and rates of 32.0 cases per 10,000 patient days from 1997 to
1999 in the ICU of a Midwestern tertiary care referral center
[4,5]. Results from our study show rates in the non-burn and
step down unit setting within this range at 15.2 cases per
10,000 patient days. Interestingly, although rates in our BICU
are higher than the national rate reported by the NNISS, at 7.9
cases per 10,000 patient days they are significantly below our
medical and surgical ICU average. The reason for this
difference is not readily clear though it is likely related to
both the rigorous infection control procedures practices in the
BICU implemented for all admitted burn patients and the
relatively young and healthy composition of most our burn
population, two factors known for decreased incidence of the
disease [7,8].
There was no clear difference in risk factors for the
acquisition of CDI either in comparing positive and negative
burn patients to one another or in comparing positive burn
patients to positive patients in the other intensive care and
step down units. Established risk factors such as number of
days in the ICU setting, number of feeding tubes and
operations, and specific antibiotic administration were either
not significant in our study or in fact counter to the previously
identified norm in that CDI negative patients tended to have
more surgeries, more feeding tubes, and longer lengths of stay
in the BICU. Similarly, though CDI positive burn patients had
significantly more surgeries and time spent in the ICU
compared to their non-burn CDI positive patients, it is likely
this is simply representative of the burn population in general
as evidencedby similar figures in theCDI negative burn patients
and thus not an indication of an independent risk factor for the
development of CDI in burn patients. Antibiotic data revealed
increased aminoglycoside use in all BICU patients relative to
patients admitted to the other intensive care and step down
units with the greatest use in CDI negative BICU patients. With
such a trend, it is unclear if these statistically significant
differences are an indication of protective benefit of the
antibiotics, absence of detrimental effect of the aminoglyco-
sides relative to other antibiotics, or some other unknown
process. There is no literature to date to suggest a protective
benefit of the drug class except possibly when given as an
alternative to another antibiotic regimen [12].
Treatment in the vast majority of cases was most often
intravenous metronidazole as is consistent with previously
established SHEA and IDSA guidelines [11]. Although there
were cases of patients receiving either oral vancomycin alone
or in combination with metronidazole, these differences were
not significant. Morbidity was low with increased hospital
stays for CDI positive burn patients relative to CDI negative
burn patients, but there were no cases of toxic colitis requiring
colectomy in either population. Both mortality and attribut-
able mortality were variable from unit to unit, but these
differences were not significant. Overall rates of attributable
mortality in the intensive care and step down unit setting were
higher than prior studies at 36% of deaths with previously
recorded values ranging from 4.87 to 6.1%, though definitions
of attributable mortality were variable in the literature. There
was, however, no attributable mortality among the BICU
patients [1,2].
It is clear that CDI continues to trouble our ICUs and
continues to remain a significant source of morbidity and
mortality. Although there were no cases requiring colectomy
and no attributable mortality in the BICU, it is likely that this is
due to the small sample size of our population and that our
study is simply underpowered as evidenced by the prevalence
of both of these in the larger sized general ICU sample. Study
results are similarly limited by the significant population
differences and retrospective nature of our study. The
electronic medical record provided by the Department of
Defense is quite robust, but nevertheless there was inconsis-
tent record of antibiotic administration during transportation
back from the theater of war for many of the CDI positive and
negative burn patients injured in recent combat operations. In
addition, it was difficult to differentiate clearly from CD
infection versus carrier state, but the CD toxins were obtained
when patients presented with a clinical syndrome consistent
with possibly CDI. Finally, it was challenging to compare
disease severity across the various wards in the study because
different disease severity scores are not applicable to all
patient populations in this study. With this in mind, further
studies with a better monitored and more representative
demographic are needed.
The fact remains despite aggressive infection control
measures in the BICU and relative health of most patients
admitted to it, CDI remains prevalent in the severely burned
population though at a low absolute rate of cases with very
limited attributable mortality. Those who do develop it have
more operations and longer length of stay, and have more
aminoglycoside use. Development of C. difficile colitis in the
BICU is not typically associated with toxic megacolon or other
complications, however, the sample size is relatively small,
and cannot be reliably compared to the approximately 5%
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incidence in other institutional ICUs. Although less suspicion
for CDI in BICU patients because of their demographics is
perhaps indicated as evidenced by the decreased incidence, it
should continue to be on the differential in a severely injured
population that regularly receives large amounts of antibiotics
and routinely requires prolonged hospitalizations. Until further
studies can be conducted in a larger, multi-center approach to
fully elucidate risks and outcomes of CDI in the BICU, continued
vigilance is warranted in this at risk population.
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